Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies
- PMID: 32549916
- PMCID: PMC7272537
- DOI: 10.1007/s13167-020-00203-4
Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies
Abstract
Cannabis-inspired medical products are garnering increasing attention from the scientific community, general public, and health policy makers. A plethora of scientific literature demonstrates intricate engagement of the endocannabinoid system with human immunology, psychology, developmental processes, neuronal plasticity, signal transduction, and metabolic regulation. Despite the therapeutic potential, the adverse psychoactive effects and historical stigma, cannabinoids have limited widespread clinical application. Therefore, it is plausible to weigh carefully the beneficial effects of cannabinoids against the potential adverse impacts for every individual. This is where the concept of "personalized medicine" as a promising approach for disease prediction and prevention may take into the account. The goal of this review is to provide an outline of the endocannabinoid system, including endocannabinoid metabolizing pathways, and will progress to a more in-depth discussion of the therapeutic interventions by endocannabinoids in various neurological disorders.
Keywords: 2-Arachidonyl glycerol; Alzheimer’s disease; Amyloid lateral sclerosis; Anandamide; Anxiety; Cancer; Cannabinoid receptor; Depression; Disease management; Endocannabinoid system; Epilepsy; Health policy; Huntington’s disease; Multi-professional expertise; Multiple sclerosis; Neurological disorder; Pain; Parkinson’s disease; Predictive preventive personalized medicine (PPPM); Schizophrenia; Stroke; Therapeutic strategies; Traumatic brain injury.
© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2020.
Conflict of interest statement
Conflict of interestThe authors declare that they have no conflict of interest.
Figures

Similar articles
-
Endocannabinoid System: A Multi-Facet Therapeutic Target.Curr Clin Pharmacol. 2016;11(2):110-7. doi: 10.2174/1574884711666160418105339. Curr Clin Pharmacol. 2016. PMID: 27086601 Review.
-
Medical Use of Cannabinoids.Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Drugs. 2018. PMID: 30374797 Review.
-
Therapeutic potential of cannabinoids in CNS disease.CNS Drugs. 2003;17(3):179-202. doi: 10.2165/00023210-200317030-00004. CNS Drugs. 2003. PMID: 12617697 Review.
-
Cannabinoids and the expanded endocannabinoid system in neurological disorders.Nat Rev Neurol. 2020 Jan;16(1):9-29. doi: 10.1038/s41582-019-0284-z. Epub 2019 Dec 12. Nat Rev Neurol. 2020. PMID: 31831863 Review.
-
The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.CNS Neurol Disord Drug Targets. 2017;16(4):370-379. doi: 10.2174/1871527316666170223161908. CNS Neurol Disord Drug Targets. 2017. PMID: 28240187 Review.
Cited by
-
Examining the role of cannabinoids on osteoporosis: a review.Arch Osteoporos. 2022 Nov 19;17(1):146. doi: 10.1007/s11657-022-01190-x. Arch Osteoporos. 2022. PMID: 36401719 Review.
-
The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders.Acta Pharmacol Sin. 2020 Dec;41(12):1507-1518. doi: 10.1038/s41401-020-00530-2. Epub 2020 Oct 6. Acta Pharmacol Sin. 2020. PMID: 33024239 Free PMC article. Review.
-
Involvement of CB2 signalling pathway in the development of osteoporosis by regulating the proliferation and differentiation of hBMSCs.J Cell Mol Med. 2021 Mar;25(5):2426-2435. doi: 10.1111/jcmm.16128. Epub 2021 Jan 29. J Cell Mol Med. 2021. PMID: 33512770 Free PMC article.
-
Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery.Int J Mol Sci. 2022 Oct 30;23(21):13223. doi: 10.3390/ijms232113223. Int J Mol Sci. 2022. PMID: 36362014 Free PMC article. Review.
-
Infections of the lung: a predictive, preventive and personalized perspective through the lens of evolution, the emergence of SARS-CoV-2 and its pathogenesis.EPMA J. 2020 Nov 13;11(4):581-601. doi: 10.1007/s13167-020-00230-1. eCollection 2020 Dec. EPMA J. 2020. PMID: 33204369 Free PMC article. Review.
References
-
- Feigin VL, Vos T. Global burden of neurological disorders: from global burden of disease estimates to actions. Neuroepidemiology. 2019;52(1–2):1–2. - PubMed
-
- WHO. Global burden of neurological disorders: estimates and projections. In: Neurological disorders: public health challenges. Geneva, Switzerland: WHO Press. https://www.who.int/mental_health/neurology/chapter_2_neuro_disorders_pu.... Accessed Jan 22 2020.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases